Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mangoceuticals, Inc. ( (MGRX) ) has shared an update.
On February 4, 2026, Mangoceuticals, Inc. disclosed that it received a deficiency notice from Nasdaq stating that the company is not in compliance with the exchange’s $1.00 minimum bid price requirement, after its common stock closed below that threshold for 30 consecutive business days. The company has 180 calendar days, until August 3, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days; Nasdaq’s notice does not immediately affect the listing or trading of the stock, but Mangoceuticals plans to monitor its share price and consider options to address the deficiency, which may influence future corporate actions and is relevant for shareholders tracking the company’s continued Nasdaq listing status.
More about Mangoceuticals, Inc.
Mangoceuticals, Inc. is a publicly traded company whose common stock is listed on the Nasdaq Capital Market, giving it access to public equity markets and exposure to U.S. retail and institutional investors.
Average Trading Volume: 1,828,247
Technical Sentiment Signal: Sell
Current Market Cap: $5.8M
For detailed information about MGRX stock, go to TipRanks’ Stock Analysis page.